Mescaline for Neuroimaging & Brain Measures

1 paper and 2 clinical trials exploring mescaline as a treatment for neuroimaging & brain measures.

CompoundPhenethylamine

Mescaline

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Full Mescaline profile

IndicationApproximately 264 million people globally suffer from depression, with PTSD affecting around 8 million adults in the United States each year.

Neuroimaging & Brain Measures

Recent advances in neuroimaging have shed light on the neurobiological mechanisms underlying the effects of psychedelics, particularly in the treatment of mental health disorders such as depression and PTSD. Studies involving compounds like psilocybin and MDMA have demonstrated significant changes in brain activity associated with therapeutic outcomes.

Full Neuroimaging & Brain Measures profile

Academic Research

1 paper

Paywallmeta

Classical hallucinogens and neuroimaging: A systematic review of human studies: hallucinogens and neuroimaging

This systematic review (2016; s=25) analyzed neuroimaging data regarding the effects of serotonergic psychedelics, including ayahuasca, psilocybin, and LSD. The study finds that these substances generally inhibit the default mode network and modulate fronto-temporo-parieto-occipital activity, correlating with increased introspection and positive mood.

Published: December 1, 2016
Journal: Neuroscience and Biobehavioral Reviews
Authors: Crippa, J. A., Dos Santos, R. G., Hallak, J. E., Osório, F. L.

Clinical Trials

2 trials

CompletedPhase I

Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness

Double-blind, placebo-controlled, 6-period crossover study (n=16) evaluating escalating oral mescaline doses (100–800 mg) and ketanserin pre-treatment in healthy volunteers aged 25–65.

Started: January 5, 2021
Type: interventional
Blinding: quadruple
Randomized: Yes
Registry ID: NCT04849013

CompletedPhase I

Comparative Acute Effects of LSD, Psilocybin and Mescaline

Double-blind, placebo-controlled, 4-period crossover study (n≈32) comparing single doses of LSD 100 µg, psilocybin 20 mg, mescaline 300/500 mg and placebo in healthy volunteers to characterise acute subjective, physiological and neural effects.

Started: May 19, 2020
Type: interventional
Blinding: quadruple
Randomized: Yes
Registry ID: NCT04227756

Explore further

Search all Mescaline papers Search all Neuroimaging & Brain Measures trials Full Mescaline profile Full Neuroimaging & Brain Measures profile